Cancer pain is an important clinical problem and may not respond satisfactorily to the current
analgesic therapy. We have characterized a novel and potent
analgesic peptide,
crotalphine, from the
venom of the South American rattlesnake Crotalus durissus terrificus. In the present work, the antinociceptive effect of
crotalphine was evaluated in a rat model of
cancer pain induced by intraplantar injection of Walker 256
carcinoma cells. Intraplantar injection of
tumor cells caused the development of
hyperalgesia and
allodynia, detected on day 5 after
tumor cell inoculation.
Crotalphine (6 μg/kg), administered p.o., blocked both phenomena. The antinociceptive effect was detected 1 h
after treatment and lasted for up to 48 h. Intraplantar injection of
nor-binaltorphimine (50 g/paw), a selective antagonist of κ-
opioid receptors, antagonized the antinociceptive effect of the
peptide, whereas
N,N-diallyl-Tyr-Aib-Phe-Leu (ICI 174,864, 10 μg/paw), a selective antagonist of δ-
opioid receptors, partially reversed this effect. On the other hand, D-Phe-
Cys-Tyr-D-Trp-Orn-Thr-Pen-Thr
amide (
CTOP, 20 g/paw), an antagonist of μ-
opioid receptors, did not modify
crotalphine-induced antinociception. These data indicate that
crotalphine induces a potent and long lasting
opioid-mediated antinociception in
cancer pain.